Skip to main content
Premium Trial:

Request an Annual Quote

Norak to Screen Against GPCRs for BASF; Extends Agreement with Lundbeck

NEW YORK, Aug. 16 (GenomeWeb News) - Norak Bioscience will use its Transfluor fluorescence cell-based assay technology to discover compounds that act against G protein-coupled receptor targets developed by BASF, Norak said.

 

Under the terms of the agreement, Norak, based in Research Triangle Park, NC, will use Transfluor to screen a selected portion of its larger compound library against GPCR targets provided by BASF, which is interested in optimizing and developing compounds for crop protection products, Norak said.

 

Financial terms of the deal were not disclosed; however, Norak said it will receive technology access and screening fees, as well as milestones and royalties.

 

Norak also announced that Lundbeck A/S has exercised its option to screen another of its GPCR targets of interest using Transfluor. The option was part of a screening collaboration agreement signed in December 2002, which stated that Norak would develop a Transfluor cell line expressing the GPCR target of interest for Lundbeck, and then screen the cell line at Norak using its high-throughput imaging systems and against a compound library of Lundbeck's choice.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.